Free Trial

Rapt Therapeutics (NASDAQ:RAPT) Receives $19.80 Consensus PT from Brokerages

Rapt Therapeutics logo with Medical background

Rapt Therapeutics (NASDAQ:RAPT - Get Free Report) has received an average recommendation of "Hold" from the seven research firms that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, two have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $21.67.

A number of equities research analysts have issued reports on RAPT shares. UBS Group cut their target price on Rapt Therapeutics from $16.00 to $8.00 and set a "neutral" rating on the stock in a research note on Thursday, May 22nd. Wall Street Zen cut Rapt Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, June 21st. HC Wainwright raised their target price on Rapt Therapeutics to $27.00 and gave the company a "buy" rating in a research note on Thursday, July 10th. Finally, Lifesci Capital raised Rapt Therapeutics to a "strong-buy" rating and set a $31.00 price target on the stock in a report on Tuesday.

Get Our Latest Stock Report on RAPT

Rapt Therapeutics Stock Up 0.8%

Shares of Rapt Therapeutics stock traded up $0.10 on Wednesday, hitting $12.75. 41,034 shares of the company's stock traded hands, compared to its average volume of 113,246. The firm's 50-day moving average is $8.75 and its 200 day moving average is $8.74. Rapt Therapeutics has a 52-week low of $5.67 and a 52-week high of $27.84. The stock has a market cap of $210.89 million, a P/E ratio of -0.66 and a beta of -0.09.

Rapt Therapeutics (NASDAQ:RAPT - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.64) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.48) by $1.84. Equities research analysts forecast that Rapt Therapeutics will post -2.14 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the stock. Sei Investments Co. bought a new position in Rapt Therapeutics in the 4th quarter worth approximately $64,000. Nuveen Asset Management LLC boosted its stake in Rapt Therapeutics by 50.5% in the 4th quarter. Nuveen Asset Management LLC now owns 116,925 shares of the company's stock valued at $185,000 after buying an additional 39,216 shares in the last quarter. Renaissance Technologies LLC boosted its stake in Rapt Therapeutics by 25.5% in the 4th quarter. Renaissance Technologies LLC now owns 369,736 shares of the company's stock valued at $584,000 after buying an additional 75,136 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in Rapt Therapeutics by 1,128.3% in the 4th quarter. JPMorgan Chase & Co. now owns 205,164 shares of the company's stock valued at $324,000 after buying an additional 188,461 shares in the last quarter. Finally, Comerica Bank acquired a new stake in Rapt Therapeutics in the 4th quarter valued at $92,000. 99.09% of the stock is owned by institutional investors.

About Rapt Therapeutics

(Get Free Report

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.

Read More

Analyst Recommendations for Rapt Therapeutics (NASDAQ:RAPT)

Should You Invest $1,000 in Rapt Therapeutics Right Now?

Before you consider Rapt Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rapt Therapeutics wasn't on the list.

While Rapt Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 “Boring” Mega Cap Stocks to Turn Into Pure Profit
Joby vs. Archer: The $10 Billion eVTOL Battle
3 Small-Cap Biotech Stocks With Catalysts Too Big to Ignore

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines